Clinical research findings
My colleagues and I compared the performance and safety of two similar OVDs that combine a dispersive and cohesive viscoelastic in a single device (Twinvisc, Carl Zeiss Meditec AG and Duovisc, Alcon Laboratories).1 These OVDs both contain hyaluronic acid, and Duovisc also includes chondroitin sulfate.
Duovisc has two syringes in one package, one with a dispersive viscoelastic (Viscoat [sodium hyaluronate 3%– chondroitin sulfate 4%]) and the other with a cohesive viscoelastic (Provisc [sodium hyaluronate 1%]) OVD. The other OVD (Twinvisc) also includes both a dispersive and cohesive OVD, but instead of two separate syringes, the solution is in a single syringe that is separated by a bypass stopper system.
A total of 200 cataract patients underwent phacoemulsification and IOL implantation in one eye. They were randomly assigned to receive one of the two OVDs. Preoperative and 3-month postoperative examinations included mean IOP, incidence of IOP peaks (≥30 mm Hg and ≥24 mm Hg), endothelial cell count (ECC), corneal thickness and intraocular inflammation.